<- Go Home
DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Market Cap
$27.1B
Volume
4.6M
Cash and Equivalents
$917.7M
EBITDA
$1.2B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$2.8B
Profit Margin
60.10%
52 Week High
$93.25
52 Week Low
$54.11
Dividend
N/A
Price / Book Value
9.87
Price / Earnings
33.71
Price / Tangible Book Value
10.22
Enterprise Value
$26.5B
Enterprise Value / EBITDA
22.11
Operating Income
$911.8M
Return on Equity
34.50%
Return on Assets
8.89
Cash and Short Term Investments
$2.0B
Debt
$1.4B
Equity
$2.7B
Revenue
$4.7B
Unlevered FCF
$731.0M
Sector
Health Care Equipment and Supplies
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium